December 15, 2011The Journal of Clinical Endocrinology & Metabolism
131IIodometomidate for Targeted Radionuclide Therapy of Advanced Adrenocortical Carcinoma
Key result
[131I]IMTO treatment in 11 patients with advanced adrenocortical carcinoma resulted in 1 partial response and 5 stable disease cases, with a median PFS of 14 months in responders.
Why the study?
Does [131I]Iodometomidate radionuclide therapy improve tumor response and provide safe treatment in patients with advanced adrenocortical carcinoma?
Population
11 patients with advanced, nonresectable adrenocortical carcinoma not amenable to radical surgery and…
Design
Case_series
Authors
Discussion
Loading...
Member takes
Implication
May support [131I]IMTO in select advanced ACC cases; leaves open efficacy and safety pending prospective trials.
Study Design
Type
Observational (n=11)
Multicenter
No
Structured PICO
Does [131I]Iodometomidate radionuclide therapy improve tumor response and provide safe treatment in patients with advanced adrenocortical carcinoma?
P
Population
11 patients with advanced adrenocortical carcinoma not amenable to radical surgery and exhibiting high uptake of [123I]IMTO in their tumor lesions.
I
Intervention
[131I]Iodometomidate ([131I]IMTO) 1.6-20 GBq administered in one to three cycles
O
Outcome
Tumor response assessed according to response evaluation criteria in solid tumors (RECIST version 1.1) and side effects assessed by Common Toxicity Criteria (version 4.0)surrogate
Targeted radionuclide therapy with [131I]Iodometomidate is well tolerated and can achieve disease stabilization or partial response in selected patients with advanced adrenocortical carcinoma.
Cite This Study
Hahner et al. (2011) conducted an observational in Advanced adrenocortical carcinoma (n=11). [131I]IMTO was evaluated on Tumor response (RECIST version 1.1) and side effects (Common Toxicity Criteria version 4.0). [131I]IMTO treatment in 11 patients with advanced adrenocortical carcinoma resulted in 1 partial response and 5 stable disease cases, with a median PFS of 14 months in responders.